Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein–induced neuropathology. In mice expressing a human α-synucleinopathy–associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein–induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.
Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj Kumar, Xiaobo Mao, Joo Ho Shin, Yunjong Lee, Olga Pletnikova, Juan C. Troncoso, Valina L. Dawson, Ted M. Dawson, Han Seok Ko
Title and authors | Publication | Year |
---|---|---|
The emerging link between O-GlcNAcylation and neurological disorders
X Ma, H Li, Y He, J Hao |
Cellular and Molecular Life Sciences | 2017 |
Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System
V Lawana, N Singh, S Sarkar, A Charli, H Jin, V Anantharam, AG Kanthasamy, A Kanthasamy |
Journal of Neuroimmune Pharmacology | 2017 |
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
D Sulzer, RN Alcalay, F Garretti, L Cote, E Kanter, J Agin-Liebes, C Liong, C McMurtrey, WH Hildebrand, X Mao, VL Dawson, TM Dawson, C Oseroff, J Pham, J Sidney, MB Dillon, C Carpenter, D Weiskopf, E Phillips, S Mallal, B Peters, A Frazier, CS Arlehamn, A Sette |
Nature | 2017 |
The c-Abl inhibitor in Parkinson disease
ZH Zhou, YF Wu, X Wang, YZ Han |
Neurological Sciences | 2017 |
Mechanisms of Parkinson’s disease-related proteins in mediating secondary brain damage after cerebral ischemia
TH Kim, R Vemuganti |
Journal of Cerebral Blood Flow & Metabolism | 2017 |
Progress toward an integrated understanding of Parkinson’s disease
MW Rousseaux, JM Shulman, J Jankovic |
F1000Research | 2017 |
CRISPR-Cas9 Mediated Telomere Removal Leads to Mitochondrial Stress and Protein Aggregation
H Kim, S Ham, M Jo, G Lee, YS Lee, JH Shin, Y Lee |
International journal of molecular sciences | 2017 |
Ubiquitin and Parkinson's disease through the looking glass of genetics
H Walden, MM Muqit |
Biochemical Journal | 2017 |
c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
S Brahmachari, SS Karuppagounder, P Ge, S Lee, VL Dawson, TM Dawson, HS Ko |
Journal of Parkinson's disease | 2017 |